Unassociated Document
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act 1934
Date of
Report (date of earliest event reported): March 31, 2010
JIANGBO
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in charter)
Florida
(State or
other jurisdiction of incorporation)
|
333-86347
|
65-1130026
|
|
(Commission File
Number)
|
(IRS Employer Identification
No.)
|
|
Middle
Section, Longmao Street, Area A, Laiyang Waixiangxing Industrial
Park
|
|
Laiyang
City, Yantai, Shandong Province, People’s Republic of China
265200
|
(Address
of principal executive offices and zip code)
(0086)
535-7282997
(Registrant's
telephone number including area code)
GENESIS PHARMACEUTICALS ENTERPRISES,
INC.
(Registrant's
former name or former address, if changed since last report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR
240.14a-12(b))
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
1.01
|
Entry
into a material Definitive
Agreement.
|
As
previously disclosed on a Current Report on Form 8-K filed with the Securities
and Exchange Commission on March 18, 2010, on October 27, 2009, Laiyang Jiangbo
Pharmaceuticals, Co., Ltd., a PRC entity (“Laiyang Jiangbo”) that Jiangbo
Pharmaceuticals, Inc. (the “Company”)
operates, controls and beneficially owns the pharmaceutical business of, entered
into a Contract for Transfer of State-Owned Construction Land Use Right (the
“Contract”) with the Land and Resources Bureau of Laiyang City (the
“Transferor”) pursuant to which the Transferor transferred the right to use a
385,800 square meter parcel of useful life of state-owned construction land to
Laiyang Jiangbo for a period of 50-years starting from the date of the execution
of the Contract. On March 31, 2010, the Contract was amended to
eliminate the requirements that (i) total investment shall be no less than
RMB868,200,000 (approximately US$127,365,000 ); and (ii) the investment
intensity shall be no less than RMB3,000 per square meter. All the other
provisions of the Contract remain unaffected and in full force. The Company
issued a press release on April 12, 2010 announcing the amendment to the
Contract. A copy of the press release is filed herewith as Exhibit 99.1 to this
current report and is incorporated by reference.
|
Item
9.01
|
Financial
Statements and Exhibits.
|
|
Exhibit
No.
|
Description
|
|
99.1
|
Press
Release dated April 12, 2010.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
| |
JIANGBO
PHARMACEUTICALS, INC. |
|
| |
|
|
|
|
|
By:
|
/s/ Wubo
Cao |
|
| |
Name: |
Wubo
Cao |
|
| |
Title: |
Chief
Executive Officer |
|
Dated:
April 12, 2010